Novartis has agreed to acquire Myricx Bio for up to $1.5 billion, securing a preclinical antibody-drug conjugate platform built around N-myristoyltransferase inhibitor payloads and two lead oncology programmes directed at B7-H3 and HER2.
The transaction, announced on July 6, 2026, includes $1.1 billion in upfront cash and as much as $400 million in milestone payments. Completion is expected during the second half of 2026, subject to customary closing conditions and regulatory approvals.
The acquisition gives Novartis control of an experimental payload technology designed to attack cancer cells through a mechanism distinct from the topoisomerase-1 inhibitors, tubulin binders and DNA-damaging agents used in most current antibody-drug conjugates. The strategic opportunity is significant, but the scientific risk remains unusually high because Myricx Bio has not yet generated human safety or efficacy data for its lead programmes.
Why is Novartis paying $1.1 billion upfront for a preclinical antibody-drug conjugate platform?
The size of the upfront payment shows that Novartis is acquiring more than two individual drug candidates. It is buying a payload platform that could potentially be combined with several tumour-targeting antibodies across multiple cancer types.
Antibody-drug conjugates are designed to use an antibody to identify a protein expressed on or near cancer cells and deliver a potent payload more selectively than conventional chemotherapy. The approach can increase drug concentration around the tumour while reducing some systemic exposure, although toxicities remain common and can limit the dose that patients receive.
Most antibody-drug conjugates in clinical development rely on a relatively small number of payload mechanisms. This concentration creates a vulnerability because tumours that become resistant to one topoisomerase-1 inhibitor payload may also respond poorly to another therapy using the same biological approach.
Myricx Bio is developing N-myristoyltransferase inhibitors as a new payload class. Novartis is effectively paying for the possibility that these compounds can open another branch of the antibody-drug conjugate market rather than competing only through a new antibody or linker attached to a familiar cytotoxic agent.
The acquisition also removes the risk that Myricx Bio’s platform could be licensed or sold to a rival pharmaceutical company. Several large drugmakers are building antibody-drug conjugate portfolios, making differentiated payload chemistry increasingly valuable as more companies pursue similar tumour targets.
How are Myricx Bio’s NMT inhibitor payloads intended to kill cancer cells differently?
N-myristoyltransferase is an enzyme that attaches a lipid called myristate to selected proteins. This modification helps those proteins adopt the correct location, stability and function inside the cell.
Many proteins dependent on this process participate in signalling, membrane organisation, stress responses and pathways required for cancer-cell survival. Blocking N-myristoyltransferase can therefore disrupt several cellular systems simultaneously rather than interfering with only one receptor or growth signal.
Myricx Bio’s strategy is to link a highly potent N-myristoyltransferase inhibitor to an antibody through an engineered linker. The antibody recognises a tumour-associated antigen and carries the payload towards malignant tissue. After internalisation and processing, the payload is released and inhibits the enzyme within the cancer cell.
This mechanism differs from topoisomerase-1 inhibitors, which damage DNA during replication, and tubulin inhibitors, which interfere with cell division. The difference could become clinically valuable when tumours have developed resistance to those established payload classes.
The NMT inhibitor approach may also affect cancers that do not divide rapidly enough to remain highly sensitive to conventional mitotic poisons. However, broad disruption of essential protein functions could create toxicity in healthy cells if the payload is released prematurely or reaches tissues expressing the selected tumour target.
Why are B7-H3 and HER2 the first targets in the Myricx Bio pipeline?
B7-H3 and HER2 are established antibody-drug conjugate targets with broad relevance across solid tumours. Both have already attracted major pharmaceutical investment, which reduces biological uncertainty around whether antibodies can reach and bind the targets effectively.
B7-H3 is expressed across several cancers, including prostate, lung, breast, head and neck, ovarian and paediatric tumours. Its presence in multiple difficult-to-treat malignancies has made it an increasingly competitive target for antibody-drug conjugates, bispecific antibodies and other immune therapies.
HER2 is one of the most clinically validated targets in oncology. HER2-directed therapies have transformed treatment in breast and gastric cancer, while newer antibody-drug conjugates have extended the opportunity into tumours with lower levels of HER2 expression.
Myricx Bio’s lead programmes combine these established targeting strategies with an unproven payload. This reduces the number of variables compared with developing a completely new antibody against an unvalidated antigen.
The trade-off is intense competition. Novartis will need to show that NMT inhibitor payloads deliver deeper responses, work after resistance to existing antibody-drug conjugates, improve tolerability or provide activity in patients whose tumours express relatively low levels of the target.
What do the preclinical results suggest about activity in treatment-resistant tumours?
Myricx Bio has reported complete and durable tumour regressions in several animal models using NMT inhibitor antibody-drug conjugates directed at B7-H3, HER2 and TROP2.
The B7-H3 programme produced tumour regressions in aggressive prostate cancer models described as poorly responsive or resistant to topoisomerase-1 inhibitor antibody-drug conjugates. A TROP2-directed programme also generated activity in breast cancer models that had previously been exposed to a topoisomerase-1 inhibitor payload.
The HER2 programme showed activity across models with varying levels of target expression and produced evidence of a bystander effect. Bystander activity occurs when the released payload moves from an antigen-positive cancer cell into neighbouring tumour cells, potentially helping the therapy attack heterogeneous tumours in which not every cell expresses the target equally.
These findings support the acquisition thesis because resistance to established payloads is becoming a larger clinical problem as patients receive successive antibody-drug conjugates. A therapy using an orthogonal mechanism could provide another treatment option after a tumour stops responding to topoisomerase-1 inhibition.
Animal tumour regressions remain an early signal rather than proof of patient benefit. Differences in tumour biology, drug metabolism, immune function and payload exposure can cause promising preclinical results to weaken or disappear during human trials.
Could NMT inhibitor payloads improve the narrow therapeutic window of current antibody-drug conjugates?
The therapeutic window describes the difference between a dose that controls the tumour and a dose that causes unacceptable toxicity. Many antibody-drug conjugates have a narrow window because some payload reaches healthy tissue through premature linker cleavage, target expression outside the tumour or normal clearance pathways.
Common toxicities associated with the wider modality include low blood-cell counts, liver injury, peripheral neuropathy, gastrointestinal effects, eye problems and interstitial lung disease. The pattern depends on the antibody, linker, payload and dosing schedule.
Myricx Bio has produced encouraging early tolerability findings in rodents and non-human primates, but those studies cannot establish the human safety profile. A new payload mechanism may avoid toxicities associated with established classes while creating different organ-specific risks.
N-myristoyltransferase contributes to normal cellular function, meaning unintended systemic exposure could affect healthy tissues. Clinical development must determine how much free payload enters circulation, which organs receive the greatest exposure and whether repeated dosing creates cumulative toxicity.
The platform’s commercial potential will depend heavily on whether Novartis can administer enough drug to produce sustained anti-tumour activity without requiring frequent dose reductions, treatment interruptions or discontinuation.
Why does the acquisition strengthen Novartis beyond the two lead antibody-drug conjugates?
Novartis can potentially apply the NMT inhibitor payload chemistry to antibodies already available within its oncology research organisation. This could create additional programmes without requiring the company to discover an entirely new payload for every target.
The platform may also support combinations with radioligand therapies, targeted medicines or immunotherapies. Novartis has built a major position in radioligand treatment, which delivers radiation to cancer cells through targeted molecules, and the company increasingly favours technologies that can generate several products rather than one isolated asset.
A successful NMT inhibitor programme could allow Novartis to create a portfolio spanning different tumour antigens, payload strengths and linker properties. It could also use diagnostic testing to identify patients whose tumours express B7-H3, HER2 or other future targets.
The acquisition therefore resembles a technology-platform investment more than a conventional purchase of a late-stage drug. Novartis is accepting substantial early clinical risk in exchange for control over intellectual property that could produce several oncology candidates.
How does the deal change the competitive antibody-drug conjugate landscape?
The antibody-drug conjugate market has expanded rapidly as clinical success has attracted large pharmaceutical companies, specialist biotechnology firms and licensing transactions involving Chinese developers.
Competition is no longer limited to identifying new tumour antigens. Companies are differentiating products through linker stability, drug-to-antibody ratio, payload potency, bystander activity and methods designed to reduce systemic toxicity.
Topoisomerase-1 inhibitors have become particularly prominent because of their activity across several solid tumours. Their growing use also increases the likelihood that future patients will enter trials after exposure to another therapy with a related payload.
Novartis is positioning NMT inhibition as a potential answer to this emerging resistance problem. If human trials confirm activity after topoisomerase-1 antibody-drug conjugates, the company could develop the platform in treatment sequences where current payload classes are losing effectiveness.
Competitors are also exploring immune-stimulating payloads, protein degraders, RNA-targeting agents and other novel mechanisms. Myricx Bio gives Novartis an early position, but it does not guarantee that NMT inhibition will become the payload class that ultimately reshapes the field.
What does the $1.5 billion price reveal about the value of differentiated oncology platforms?
The transaction includes $1.1 billion upfront, representing the majority of the maximum consideration. Only $400 million is contingent on future milestones.
This structure places significant risk on Novartis because the acquired programmes remain preclinical. In many biotechnology transactions, buyers defer a larger percentage of the total value until clinical, regulatory or commercial milestones are achieved.
The unusually high upfront component suggests that competitive interest, platform ownership and the scarcity of differentiated payload technologies influenced the price. Myricx Bio had strengthened its negotiating position through a £90 million Series A financing, an experienced antibody-drug conjugate team and plans to begin clinical development in 2026.
The deal also demonstrates how quickly high-quality academic science can create value when paired with focused venture funding. Myricx Bio was founded in 2019 from research associated with Imperial College London and the Francis Crick Institute before progressing into a transatlantic biotechnology company.
The valuation will appear justified only if the platform generates one or more clinically successful products. A single approved oncology drug could support substantial commercial value, while early toxicity or insufficient efficacy could impair most of the acquisition.
What are the most important risks before the first NMT inhibitor antibody-drug conjugate reaches patients?
The first challenge is manufacturing a stable antibody-drug conjugate with consistent payload attachment, linker performance and product quality. Small changes in conjugation can affect distribution, potency and toxicity.
The second is selecting a starting dose that is low enough to protect patients but high enough to generate interpretable pharmacological data. First-in-human studies must examine free payload exposure, target engagement, tumour response and early organ toxicities.
Patient selection will also matter. B7-H3 and HER2 expression can vary between tumour types and within different areas of the same tumour. Novartis must determine whether antigen level predicts response and whether bystander activity can compensate for heterogeneous expression.
Another risk is that resistance to topoisomerase-1 payloads may arise through mechanisms unrelated to the payload itself, including reduced antigen expression, impaired internalisation or drug-efflux changes. Switching to NMT inhibition may not overcome every reason that a previous antibody-drug conjugate failed.
Novartis must also establish whether the new payload can be combined safely with immune checkpoint inhibitors, targeted drugs or other oncology treatments. Combination therapy may expand efficacy but can make toxicity attribution more difficult.
How soon could the acquisition produce clinically meaningful evidence?
Myricx Bio had previously planned to begin human testing of its lead development candidate during 2026. The acquisition could preserve or accelerate that timeline because Novartis has global clinical-development infrastructure, regulatory teams and manufacturing resources.
Early Phase 1 development will primarily establish safety, dose, pharmacokinetics and preliminary anti-tumour activity. Meaningful validation would require responses in patients with advanced solid tumours, particularly those previously treated with antibody-drug conjugates using established payload classes.
The strongest early signal would combine tumour shrinkage with manageable safety and activity across patients whose disease had progressed after a topoisomerase-1 inhibitor antibody-drug conjugate. Evidence of benefit in low-antigen tumours would further support the reported bystander effect.
Even a promising Phase 1 result would leave several years of development before potential approval. Novartis must identify the correct tumour populations, compare dosing schedules and decide whether to prioritise broad tumour baskets or specific cancers.
What does the acquisition mean for Novartis investors and market sentiment?
Novartis American depositary receipts traded near $155.49 on July 7, declining approximately 2.8% from the previous close and giving the company a market value above $300 billion.
The subdued share reaction reflects the relative scale of the transaction. A $1.1 billion upfront payment is substantial for a preclinical biotechnology acquisition but remains manageable for a global pharmaceutical company of Novartis’ size.
The acquisition will not contribute near-term product revenue and will increase research and development spending as the programmes move into clinical trials. Investors are therefore likely to judge the transaction through pipeline value rather than immediate earnings accretion.
The strategic sentiment is more constructive. Novartis gains a differentiated oncology platform without committing the much larger capital required to acquire a company with an approved antibody-drug conjugate.
The main concern is execution risk. The upfront payment limits Novartis’ ability to protect itself financially if the first clinical programme fails, while competition may advance quickly during the years required to establish human proof of concept.
Could the Myricx Bio acquisition become a model for how Novartis builds oncology platforms?
Novartis has shown a preference for technologies that can support several medicines across different cancers. Its expansion in radioligand therapy demonstrated how acquiring specialised scientific capabilities can create a broader product engine.
Myricx Bio offers a similar strategic possibility within antibody-drug conjugates. The acquired chemistry could be paired with multiple antibodies, while Novartis’ scale could accelerate manufacturing, translational research and clinical testing.
The comparison should not be overstated. Radioligand therapy has already produced approved products and substantial sales. NMT inhibitor antibody-drug conjugates have not yet entered human trials.
The acquisition therefore represents an attempt to recreate a platform-building strategy at a much earlier and riskier stage. Success would give Novartis a proprietary payload class with applications across several solid tumours. Failure would leave the company with expensive preclinical technology that never crossed the therapeutic window in patients.
Does the acquisition materially improve treatment prospects for patients with resistant solid tumours?
The scientific rationale addresses a genuine clinical problem. Patients increasingly receive multiple targeted therapies and antibody-drug conjugates, creating a need for treatments that remain active after resistance to common payloads develops.
NMT inhibition could provide a different way to kill cancer cells while preserving the targeting advantages of the antibody-drug conjugate format. The B7-H3 and HER2 programmes also focus on antigens with relevance across several high-need tumour types.
My assessment is that Novartis has acquired one of the more differentiated preclinical payload technologies in the antibody-drug conjugate sector, but the transaction remains a high-cost scientific wager rather than a near-term clinical breakthrough.
The preclinical tumour regressions, activity in models resistant to topoisomerase-1 payloads and early non-human primate tolerability justify human development. They do not establish that the same balance of efficacy and safety will be achieved in patients.
The decisive milestone will be the first clinical dataset showing that an NMT inhibitor antibody-drug conjugate can produce meaningful responses at tolerable doses. Until then, the $1.5 billion acquisition should be understood as Novartis buying the opportunity to create a new payload class, not proof that it has already done so.
